Abstract:BACKGROUNDThe objective of this study was to investigate the antitumor activity of selectively expanded gammadelta T cells in tumor-infiltrating lymphocytes (gammadeltaTILs) or tumor ascites lymphocytes (gammadeltaTALs) from patients with colorectal and ovarian epithelial carcinoma (OEC) in vitro and in vivo.METHODSgammadeltaTILs/TALs were expanded by the solid-phase antibody method; their cytolytic and proliferative activities in vitro were detected by the MTT method and 3H-TdR incorporation and their effect in vivo was evaluated by the nude mice model.RESULTSExpanded gammadeltaTILs from colorectal tumors demonstrated marked cytotoxicities to allogeneic human colon adenocarcinoma HR8348 and lymphoma Daudi cells, as well as xenogeneic murine thymoma EL-4 cell lines. Cytokines, including IL-2, IL-4, IL-12, IL-15, TNF-alpha and INF-gamma, could promote the cytotoxicities of gammadeltaTILs to tumor cells, whereas IL-10, GM-CSF and TFG-beta had no effect on such killing activities. Rested gammadeltaTILs could proliferate strongly in response to mitomycin C-treated Daudi and EL-4 tumor cells, but not to HR8348 tumor cells, suggesting that the latter might possess only cytotoxicity-related antigen recognized by gammadeltaTILs. Either alphabetaTILs or gammadeltaTILs from patients with OEC displayed cytotoxicities to allogeneic or autologous OEC cell lines at a similar strength in vitro. Transferring gammadeltaTILs into Daudi cell-bearing BALB/c nude mice with an injection of IL-2 was able to maintain a high survival rate of the mice for 30 days, when compared with mice treated with alphabetaTILs or without any treatment (p < 0.05). Without coinjection of IL-2, after 3 months of Daudi tumor inoculation, a high survival rate was observed in gammadeltaTIL-treated mice. Similarly, adoptive gammadeltaTALs from the ascites of patients with OEC transferred into nude mice displayed a stronger antitumor response to OEC SKOV3 cells than alphabetaTALs in vivo. Tumor volumes in gammadeltaTAL-treated mice were smaller than in alphabetaTAL-treated or non-TAL-treated mice within the period from day 23 to day 50 after tumor inoculation (p < 0.05). Fifty days after SKOV3 tumor inoculation, a decreasing trend of carcinogenic rate was observed in gammadeltaTAL-treated nude mice.CONCLUSIONTaken together, our results suggest that gammadeltaT cells could be a new candidate for adoptive immunotherapy in the future treatment of patients with cancer.

Effect of γδT Cells in Tumor

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in Vitro

Antitumor Activity of Expanded Human Tumor-Infiltrating Gammadelta T Lymphocytes.

The Microbiota is a Potential Mediator of the Crosstalk Between Γδ T Cells and Tumors

Research Progress of γδT Cells in Tumor Immunotherapy

γδ cell-based immunotherapy for cancer

In respond to commensal bacteria: γδT cells play a pleiotropic role in tumor immunity

Gamma-delta (γδ) T cells: friend or foe in cancer development?

Study on the effect of γδ T cells expanded in vitro to kill hepatocellular carcinoma cells

Function of γδ T cells in tumor immunology and their application to cancer therapy

γδ T cells as critical anti-tumor immune effectors

γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells

Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

In Respond To Commensal Bacteria: Gamma Delta T Cells Play A Pleiotropic Role In Tumor Immunity

Human Γδt-Cell Subsets and Their Involvement in Tumor Immunity.

γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion

Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy

The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy